Incidentally, a phase 2 study of dasatinib for the treatment of KIT-positive recurrent and metastatic ACC revealed 50% stable disease and, therefore, the MYB-suppressing effects of Src-family/KIT inhibitors might be of relevance for ACC therapy too[172]. This evidence concerns the gene MYB and adrenal cortex carcinoma.